Teva launches generic ADHD treatment

INTUNIV had total market sales of $804 million in the US, according to IMS data as of March 2015.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the launch of the generic equivalent to INTUNIV (guanfacine) in 1 mg, 2 mg, 3 mg, and 4 mg dosages, in the US. Guanfacine extended-release tablets are a non-stimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) that can be used alone, or as an add-on to stimulant medications.

ADHD is the most common neurobehavioral disorder diagnosed in children in the US. ADHD affects 1 in 10 US children and half of these children are diagnosed by the age of six. Guanfacine extended-release tablets join Tevas current generic line of seven ADHD products, said Teva president and CEO North America Generic Medicines Brendan OGrady. We recognize the need to make affordable generic treatment options available to patients with ADHD.

INTUNIV had total market sales of $804 million in the US, according to IMS data as of March 2015.

Published by Globes [online], Israel business news - www.globes-online.com - on June 2, 2015

Copyright of Globes Publisher Itonut (1983) Ltd. 2015

 
Twitter Facebook Linkedin RSS Newsletters Israel Business Conference 2018